A review published in 2022 in the journal NanoImpact evaluated the latest research related to genotoxic effects of titanium dioxide through in vivo studies and in vitro cell tests. Researchers summarized the results by stating TiO2 nanoparticles “could induce genotoxicity prior to cytotoxicity,” and “are likely to be genotoxic to humans.”
The supply in North America remained adequate, as companies were seen constantly altering their production rates in response to the volatility in the demand pattern. In the final week of September, news of Chemours' forthcoming titanium dioxide factory in Georgia valued USD 86 million alleviated fears about supply strain.